Primary Category:
Treatment Protocols
Disease Category:
Lung, Lung - Non-Small Cell, Lung - Non-Small Cell Metastatic
Status:
Open
Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Eligible for screening study DCP 001
NCT#04181060
